Jose Luis Ruiz Sepúlveda, Associate Director, Clinical Scientist – Early Oncology, Clinical Development at AstraZeneca, shared on LinkedIn:
“Finally, the core publication from my PhD thesis is out.
I’m deeply grateful to Miguel Quintela-Fandino and Rebeca Jimeno for their guidance, and to the Breast Cancer Unit at CNIO – Spanish National Cancer Research Centre and all collaborators for their dedication throughout the revision process. Grateful for your support and commitment.
Osteopontin mediates acquired resistance to hypoxia‑inducing antiangiogenics and promotes anti–PD‑L1 refractoriness in breast cancer models.”
Title: Osteopontin mediates acquired resistance to hypoxia-inducing antiangiogenics and promotes anti–PD-L1 refractoriness in breast cancer models
Authors: Jose Luis Ruiz-Sepulveda, Maria J. Bueno, Silvana Mouron, Veronica Jimenez-Renard, Manuel Muñoz, Manuel Moradiellos, Leonardo D. Garma, Luis García-Jimeno, Adam W. Watson, Ghassan Mouneimne, Solip Park, Rebeca Jimeno, Miguel Quintela-Fandino
Other articles about breast cancer on OncoDaily.